[Shanghai Yizhong: paclitaxel polymer micelles for injection included in the guidelines for the diagnosis and treatment of non-small cell lung cancer of the Chinese Society of Clinical Oncology (2023)] Science and Technology Innovation Board Daily on the 23rd, Shanghai Yizhong announcement, the company recently learned from the 2023CSCO guidelines of the Chinese Society of Clinical Oncology (CSCO) that the company's core product paclitaxel polymer micelles for injection was included in the "Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of non-small cell lung cancer (2023)." Combined with platinum for first-line treatment of Ⅳ phase non-driving gene, squamous cell carcinoma and non-squamous cell lung cancer (NSCLC) (class I recommended class 1A evidence).